June 6, 2023
Kidswell Bio Corporation
Code: 4584 (Growth Market, TSE)
Masaharu Tani, President & CEO

Announcement of appointment of New CEO and Board Directors
Tokyo, June 6, 2023 –At the Board of Directors meeting today, Kidswell Bio Corporation (hereafter KWB)
resolved to put the appointment of the following President & CEO and Directors of the Board into theagenda of the 23rd ordinary general meeting of shareholders to be held on June 29, 2023.
1. Change of President & CEO(1) Candidate of President & CEO (To be appointed on June 29, 2023)
Name

Current title

Shinya Kurebayashi

President & CEO

New position
Corporate Officer, Chief
Business Officer(2) Reasons for the appointment
For the achievement of our Mid-Term Strategic Plan -KWB 2.0-, Shinya Kurebayashi has been mainly
conducting a wide range of activities in the biosimilar business and the regenerative medicine business,such as searching for new partner companies, negotiating partnerships, strengthening relationships withpartners, and raising funds. Under the leadership of Shinya Kurebayashi, KWB will respond to changes
in the environment surrounding KWB and make flexible, timely, prompt, and appropriate management
decisions and promotions, and improve our corporate value.
(3) Details of new CEO
New title

President & CEO

NameShinya Kurebayashi

Date of birth

December 28, 1976

Education

Massachusetts Institute of Technology, MSc, Physics

Biography

Apr. 2004

Joined Goldman Sachs Japan

Aug. 2009

Joined Morgan Stanley (Mitsubishi UFJ Morgan Stanley
Securities)

Oct. 2014

Jointed ImPACT of Cabinet Office

Sep. 2015

Joined Advanced Cell Technology and Engineering LTD (ACTE)
as Business Administration Officer

Jun. 2016

Board Director and Business Administration Officer, ACTE

Aug. 2016

Board Director and General Manager of Corporate Planning &Business Administration Div., ACTE
1Jan. 2018
Mar. 2019
Mar. 2021
Numbers ofshares owned

Board Director, Executive Vice President, Director ofRegenerative Medicine Business Div. and General Manager ofBusiness Div., ACTE
Joined Kidswell Bio Corporation (f/k/a Gene Techno Science
Co., Ltd.) as Corporate Officer, Chief Business Officer (To thepresent)
Board Director, Japan Regenerative Medicine (JRM)

87,000 shares as of June 6, 2023

2. Changes of Directors(1) Director candidates
Name

New title

Shinya Kurebayashi

President & CEO

Masayuki Kawakami

Board DirectorNorikazu Eiki

Board Director (Outside)

Current title
Corporate Officer, CBO,
Business Development Div.
Corporate Officer, COO,
Research & Development Div.
Reappointed(Note) Norikazu Eiki is a candidate for outside director stipulated in the Companies Act.
(2) Details of New Director of the Board
New title

Director

Name

Masayuki Kawakami

Date of Birth

April 10, 1964

Education

Kyoto Univ. Graduate School of Engineering, Ph.D.

Biography

Apr. 1989
Nov. 2001
Apr. 2007
Dec. 2009
Apr. 2012
Apr. 2017

Numbers ofshares owned

Joined FUJIFILM Corp.
Visiting Researcher, Kyoto Univ. Department of SyntheticChemistry and Biological Chemistry
Research Manager, Research laboratories, FUJIFILM Corp.
Manager, FUJIFILM Toyama Chemical Co., Ltd. (f/k/a Toyama
Chemical Corp.)
Director, FUJIFILM Pharmaceuticals USA, Inc.
Joined Kidwell Bio Corporation (f/k/a Gene Techno ScienceCo., Ltd.) as Director of Business Development Div.

Mar. 2018

Corporate Officer, Chief Technology OfficeFeb. 2020

Board Director, Japan Regenerative Medicine Co., Ltd. (JRM)

Mar. 2021

President, JRM

Nov. 2022

Corporate Officer, Chief Operating Officer (To the present)
2,500 shares as of June 6, 20232

(3) Reasons for the appointment
For the reason for the appointment of Shinya Kurebayashi, please see “1. Change of President & CEO,(2) Reasons for change” above.
In KWB’s biosimilar business as our revenue foundation, Masayuki Kawakami has engaged in the launchof three biosimilar products that required research and development using advanced biotechnology andhas been promoting the establishment of continuous cost reduction. In addition, Masayuki Kawakami
has greatly contributed to the progress of the research and development of SHED (stem cells form human
exfoliated deciduous teeth) at KWB.
(4) Scheduled Date of Appointment
June 29, 2023, at the 23rd ordinary general meeting of shareholders
5. Resignation
NameCurrent title

Masaharu Tani

President & CEO

Aya Chiba

Director

About Kidswell Bio Corporation (KWB)
Kidswell Bio Corporation will challenge pediatric disease as a new field, in addition to intractable and rarediseases on which KWB has also been focusing for R&D. We would like to contribute to children who
have hopes and dreams for their bright future. Furthermore, with our biotech expertise and children’s
potential vital force such as SHED, we envision creating new pharmaceuticals and therapeutics for all
people under “Kids Well, All Well.”Contact:
Kidswell Bio Corporation
Tel: +81-3-6222-9547

Mail: info@kidswellbio.com

3